Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK) analyses and physiologically based biopharmaceutics model(s) (PBBM(s)) have been issued. Workshops are routinely held, demonstrating substantial interest in applying these modeling approaches to address scientific questions in drug development. PBPK models and PBBMs have remarkably contributed to model-informed drug development (MIDD) such as anticipating clinical PK outcomes affected by extrinsic and intrinsic factors in general and specific populations. In this review, we proposed practical considerations for a "base" PBPK model construction and development, summarized current status, challenges including model validation and gaps in system models, and future perspectives in PBPK evaluation to assess a) drug metabolizing enzyme(s)- or drug transporter(s)- mediated drug-drug interactions b) dosing regimen prediction, sampling timepoint selection and dose validation in pediatric patients from newborns to adolescents, c) drug exposure in patients with renal and/or and hepatic organ impairment, d) maternal-fetal drug disposition during pregnancy, and e) pH-mediated drug-drug interactions in patients treated with proton pump inhibitors/acid-reducing agents (PPIs/ARAs) intended for gastric protection. Since PBPK can simulate outcomes in clinical studies with enrollment challenges or ethical issues, the impact of PBPK models on waivers and how to strengthen study waiver is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Terfenadine is also the canonical example that PBPK platforms now explicitly address through metabolite-linked parent models and DDI simulations [22,84,85].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“and predictivity for poorly soluble, formulation-sensitive compounds depends heavily on the quality of dissolution and precipitation modelling inputs [12,84,91].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“overparameterization may yield apparent good fits without genuine predictive validity;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“uncertainty propagation through complex models can produce confidence intervals that under-represent true predictive uncertainty;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
In the citing paper
“Regulatory acceptance varies by intended impact: supportive PBPK contextualizing other data is widely accepted; decision-enabling PBPK that drives dose recommendations or DDI labelling demands closer scrutiny; and label-replacing PBPK substituting for dedicated clinical studies remains the most stringently reviewed category, restricted to thoroughly verified contexts of use [22,84,85].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [84]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Onset of Maternal Arterial Blood Flow and Placental Oxidative Stress
Jauniaux, E., Watson, A. L., Hempstock, J., Bao, Y.-P., Skepper, J. N., & Burton, G. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64849-3 · Cited by 1,057
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD
Durand, F., & Valla, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.015 · Cited by 656
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Verbeeck, R. K. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0553-z · Cited by 652
Pregnancy-Induced Changes in Pharmacokinetics: A Mechanistic-Based Approach
Anderson, G. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00001 · Cited by 648
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488 · cited 1×
“There is limited experience in IVIVE and PBPK modeling for nonCYP enzymes (such as, UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), carboxylesterases (CESs), and aldehyde oxidase (AO)) while case examples are emerging (21, 22, 164).”
BackgroundSelf-citation
Research works printed but not linked: 8
- FDA. M-CERSI Workshop: Assessing Changes in Pharmacokinetics of Drugs in Liver Disease. 2020.
- Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications Philadelphia : Wolters Kluwer Health/Lippincott William & Wilkins, 2011.
- Lin W, Yan J, Heimbach T, He H. Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges. J Pharm Sci. 2018;4:491–501.
- Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, Heimbach T. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. J Pharm Sci. 2019;108(1):87–101. · DOI
- Edlund H, Bellanti F, Liu H, Vishwanathan K, Tomkinson H, Ware J, Sharma S, Buil-Bruna N. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach. British Journal of Clinical Pharmacology;n/a(n/a).
- Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H, Bloomer JC, Tal-Singer R, Lazaar AL. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects. BMC Pharmacol Toxicol. 2015;16(1):18. · DOI
- Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL. Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations. Eur J Pharm Biopharm. 2017;117:224–31. · DOI
- Keyvanjah K, Fang P, Cooke B, DiPrimeo D, Pearl J, Dyla S, Hunt D, Rubets I, Wong A, Martin D. A drug-drug interaction study evaluating the effect of multiple doses of ranitidine administered once daily or staggered twice daily on the pharmacokinetics and safety of neratinib in healthy subjects. JACCP journal of the american college of clinical pharmacy. 2018;1(2):123‐.
Cited by
Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030332 · Cited by 390
Deepika, D., & Kumar, V. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043473 · Cited by 108
Malheiro, V., Santos, B., Figueiras, A., & Mascarenhas‐Melo, F. (2025) · Pharmaceuticals · doi:10.3390/ph18060788 · Cited by 100
In Silico ADME Methods Used in the Evaluation of Natural Products
Ancuceanu, R., Lascu, B. E., Drăgănescu, D., & Dinu, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081002 · Cited by 96
Wu, D., & Li, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03373-0 · Cited by 60
Self-citation
Metadata
- Authors
- Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T.
- Affiliations
- Janssen Research & Development (United States) (US)
- Genentech (US)
- University of Washington (US)
- United States Food and Drug Administration (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Zhang, Xinyuan
- Venue
- Pharmaceutical Research
- Published
- 2022-05-13
- Volume
- 39
- Issue
- 8
- Pages
- 1701-1731
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W4280544609
- Cited by
- 137
- References
- 173
- Citations by year
- 2026: 18 · 2025: 40 · 2024: 43 · 2023: 24 · 2022: 12
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- physiologically based pharmacokinetic modeling, physiologically based biopharmaceutics modeling, model-informed drug development, regulatory guidelines, model validation, drug-drug interactions, drug-metabolizing enzymes, drug transporters, pediatric dosing, renal dysfunction, liver dysfunction, pregnancy, proton pump inhibitors, acid-reducing agents
- MeSH terms
- Adolescent, Biopharmaceutics, Child, Computer Simulation, Drug Interactions, Humans, Infant, Newborn, Models, Biological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. https://app.cochat.ai/papers/10.1007/s11095-022-03274-2
- The paper
- Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022). Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharmaceutical Research. https://doi.org/10.1007/s11095-022-03274-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.